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Abstract 
Background: Reperfusion therapy is known to improve prognosis and limit 
myocardial damage after myocardial infarction (MI). The administration of 
antiplatelet drugs prior to percutaneous coronary intervention also proves beneficial 
to patients with acute MI (AMI). However, a good number of AMI patients do not 
receive reperfusion therapy, and it is not clear if they would benefit from antiplatelet 
pre-treatment. 
Methods: Experimental C57BL/6 mice were randomly allocated to five groups: the 
sham group, control, post-treatment, pre-treatment, and pre- and post-treatment 
groups. Aspirin (15 mg/kg), clopidogrel (11 mg/kg), ticagrelor (27 mg/kg), and 
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prasugrel (1.5 mg/kg) were intragastrically administered in the treatment groups. On 
day 7 post MI, cardiac function and cardiac fibrosis were evaluated using 
echocardiography and Masson’s Trichrome staining respectively. Histopathological 
examinations were performed on tissue sections to grade inflammatory cell 
infiltration. Platelet inhibition was monitored by measuring thrombin-induced platelet 
aggregation.  
Results: Left ventricular ejection fraction and fractional shortening improved 
significantly (p < 0.01) in the pre-treatment groups when compared to the 
post-treatment and control groups. A significant (p < 0.01) decrease in cardiac 
fibrosis was observed in the pre-treatment group, compared with the post-treatment 
and control groups. Inflammatory cell infiltration significantly decreased in the 
pre-treatment group compared with the control group (p < 0.05). Thrombin-induced 
platelet aggregation was significantly inhibited by antiplatelet drugs, but increased 
with the exposure to H2O2. 
Conclusions: In the absence of reperfusion therapy, pre-treatment with antiplatelet 
drugs successfully improved cardiac function, reduced cardiac fibrosis and 
inflammatory cell infiltration, and inhibited oxidative stress-induced platelet 
aggregation after MI in the mouse model. 
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Acute myocardial infarction (AMI) is the most severe manifestation of coronary 
artery disease [1]. Prompt recanalization of the culprit vessel and restoration of blood 
flow to the myocardium are the main therapeutic goals in AMI. Currently, 
percutaneous coronary intervention (PCI) and thrombolytic therapy are used for 
effective reperfusion, improving blood flow and preventing recurrent ischemia [2, 3]. 
Nevertheless, studies have suggested that there is a great variation in the provision of 
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reperfusion therapy [5]. Although the rate of early reperfusion therapy for myocardial 
infarction (MI) has reached a fairly high level in many developed countries. In 
developing countries, such as China, during the decade 2001–2011, outcomes of 
in-hospital treatment for ST-segment elevation MI (STEMI) patients have not 
improved significantly: the proportion of patients receiving reperfusion therapy has 
not increased. The treatment of STEMI patients is still significantly delayed, and 
more than half of STEMI patients miss the opportunity of reperfusion therapy due to 
delayed consultation [4].  
Antiplatelet drugs have been the cornerstone of secondary prevention in patients 
with coronary heart disease, and these agents have significantly reduced the mortality 
and have improved the prognosis. Double antiplatelet therapy (DAPT) is a pivotal 
treatment strategy for patients with AMI and has been recommended in many 
guidelines [2, 3, 6]. In recent years, assessment of the most appropriate timing for 
initiating the administration of antiplatelet drugs has been focused upon on with great 
interest. Many studies [7, 8] have shown the administration of antiplatelet drugs prior 
to PCI to be beneficial in patients with MI. Brener et al. [8] suggested that 
acetylsalicylic acid (ASA) pretreatment reduced the mortality at 30 days, especially 
in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). 
However, the benefits of pretreatment with antiplatelet drugs in patients with MI who 
do not receive reperfusion therapy are not clear. The aim of this study was to evaluate 
the effects of pretreatment with antiplatelet drugs on cardiac function after MI in a 
mouse MI model. 
 
METHODS 
Reagents and materials 
Apyrase and prostaglandin E1 were purchased from Sigma-Aldrich Corporation 
(St. Louis, MO, USA). Thrombin was obtained from Enzyme Research Laboratories 
(South Bend, IN, USA). CD45 antibody was obtained from Bio-Rad (Hercules, CA, 
USA). Biotinylated goat anti-rat antibody was obtained from Vector (Burlingame, CA, 
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USA). ASA was obtained from Bayer Health Care (Leverkusen, Germany), ticagrelor 
was obtained from AstraZeneca PLC (Shanghai, China), clopidogrel was purchased 
from Sanofi Winthrop Industrie (Shanghai, China), and prasugrel was purchased 
from Bio tool (Houston, TX, USA). Prasugrel and clopidogrel active metabolites 
were purchased from Shanghai Race Chemical Co., Ltd. (Shanghai, China). The 
Masson Stain Kit was obtained from Shanghai Yeasen Biological Technology Co., 
Ltd. (Shanghai, China).  
 
Animals 
C57BL/6 male mice (8-weeks-old) were purchased from the Shanghai Slack 
Laboratory Company (Shanghai, China). The mice were anesthetized by 
intraperitoneal injection of pentobarbital sodium (50 mg/kg) and were then 
exsanguinated to retrieve blood and heart. Pentobarbital sodium (200 mg/kg, 
intraperitoneally) was used to euthanize the mice at the end of the experiments. The 
Shanghai Jiao Tong University School of Medicine Animal Care and Use Committee 
approved the animal research protocol. All animal procedures conformed to NIH 
guidelines (Guide for the Care and Use of Laboratory Animals). 
 
Experimental design 
The mice were randomly divided into five groups: (1) sham operation group — 
a suture was passed under the left anterior descending (LAD) coronary artery without 
ligation; (2) control group — MI was induced using the model described below, and 
the same vehicle was administered intragastrically; (3) post-treatment group — after 
MI induction, mice were given ASA (15 mg/kg), clopidogrel (11 mg/kg), ticagrelor 
(27 mg/kg), or prasugrel (1.5 mg/kg) by intragastric administration for 7 days; (4) 
pre-treatment group — before MI induction, ASA (15 mg/kg), clopidogrel (11 mg/kg), 
ticagrelor (27 mg/kg), or prasugrel (1.5 mg/kg) was orally administered to the mice 
for 7 days; (5) pre- and post-treatment group — for 7 days prior to and for 7 days 
after MI induction, ASA (15 mg/kg), clopidogrel (11 mg/kg), ticagrelor (27 mg/kg), 
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or prasugrel (1.5 mg/kg) was orally administered to the mice. In each group, 10 mice 
were treated with each of the drugs. The drugs were dissolved in normal saline. For 
each drug, the dose selection was based on the human clinical dosage: ASA (100 
mg/60 kg), clopidogrel (75 mg/60 kg), ticagrelor (90 mg/60 kg), or prasugrel (10 
mg/60 kg). 
 
Myocardial infarction model 
The mice were housed in a temperature-controlled environment with 12-h 
light/12-h dark cycles. MI was induced by permanent ligation of the LAD coronary 
artery, as described previously [9]. Eight-week-old mice were anesthetized by 
isoflurane inhalation. A rodent ventilator (Model 683, Harvard Apparatus, Inc., 
Holliston, MA, USA) was used with 65% oxygen during the surgical procedure. The 
animals were kept warm using heat lamps and heating pads. A left thoracotomy was 
performed in the fourth intercostal space. The heart of the mouse was exposed, and 
the LAD coronary artery was ligated, 2 mm from its ostial origin, with a 7-0 silk 
suture. Regional ischemia was confirmed by changes in the electrocardiogram 
(ST-segment elevation). A sham operation involved the same procedure, but a suture 
was passed under the LAD coronary artery without ligation. 
 
Echocardiography  
Echocardiography was performed using a Vevo 770 high-resolution imaging 
system at day 7 after MI induction as described previously [9]. The animals were 
anesthetized with isoflurane inhalation and placed in the supine position. The chest 
was shaved, and parasternal short- and long-axis views were used to obtain 
two-dimensional and M-mode images by echocardiography. At least 10 independent 
cardiac cycles were obtained for each measurement.  
 
Masson's trichrome staining  
The hearts were harvested at the end of the study and were perfused and fixed in 
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formalin. Parasternal short-axis sections were cut before staining with Masson 
Trichrome reagent. The slides were analyzed and photographed with an AXIO 
ScopeA1 microscope (ZEISS Group, Jena, German). The area of cardiac fibrosis 
(blue collagen staining for scar tissue) was expressed as a percentage of the left 
ventricular (LV) surface area by using ImageJ software (National Institutes of Health, 
Bethesda, MD, USA).  
 
Platelet preparation and aggregation 
The washed platelets from wild-type mice were prepared as previously 
described [10]. These were adjusted to a density of 3 × 108 platelets/mL. The platelets 
were evaluated for aggregation with reactive oxygen species (ROS)-induced stress 
with thrombin. They were incubated with H2O2 (200 μmol/mL) for 3 min and then 
with ASA, the clopidogrel active metabolite, ticagrelor, or the prasugrel active 
metabolite for 3 min, and platelet aggregation was induced by thrombin.  
 
Immunohistochemistry 
Myocardial tissue was fixed in formalin for 24 h and then embedded in paraffin. 
The parasternal short-axis sections were cut into 4 μm-thick slices. To quench the 
endogenous peroxidase activity the sections were deparaffinized and incubated with 3% 
hydrogen peroxide for 10 min at room temperature. The sections were layered with 
the anti-CD45 polyclonal antibody (1:500) at 4°C overnight and were subsequently 
washed 3 times with phosphate buffered saline (PBS) for 5 min each. The sections 
were incubated with secondary goat anti-rat antibody labeled with biotin for 30 min 
at 37°C and then visualized with diaminobenzidine using an AXIO ScopeA1 
microscope (ZEISS Group, Jena, German). The CD45-positive cells were counted in 
5 to 10 myocardial views per section with ImageJ software. 
 
Statistical analysis 
Data are presented as means ± standard error. The statistical significance of 
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multiple treatments was determined using the GraphPad Prism Software Version 5.9 
(San Diego, CA, USA) by the Student t-test or ANOVA (one-way and two-way), 
followed by either a Newman-Keuls or Bonferroni post hoc test, when appropriate. 
The values of p < 0.05 were considered statistically significant. 
 
RESULTS 
ASA, clopidogrel, ticagrelor, and prasugrel pretreatment improves cardiac 
function after MI 
The representative M-mode echocardiograms, performed on day 7 after MI, 
from each group are shown in Figure 1A. Compared with the control group, 
significant changes in left ventricular ejection fraction (LVEF) and left ventricular 
fractional shortening (LVFS) were observed in the pre-treatment, pre- and 
post-treatment, and post-treatment groups. In the groups that were pretreated with 
ASA, clopidogrel, ticagrelor, or prasugrel, the cardiac function was significantly 
preserved compared to that in the post-treatment and control groups (Fig. 1B–I). The 
differences between the control and pre-treatment groups were statistically significant 
(p < 0.01). Among the four drugs, clopidogrel was less effective in improving the 
mouse cardiac LVEF and LVFS compared with ASA, ticagrelor, and prasugrel in the 
pre-treatment, pre- and post-treatment, and post-treatment groups (Fig. 1J, K); 
significant differences (p < 0.05) were observed in these cases. 
 
ASA, clopidogrel, ticagrelor and prasugrel pretreatment decreases cardiac 
fibrosis after MI 
After MI, the initial reparative fibrosis is crucial in preventing the rupture of the 
ventricular wall, but an exaggerated fibrotic response is detrimental and results in 
progressive impairment of cardiac function [11]. Cardiac fibrosis with the Masson 
trichrome staining on day 7 after MI was evaluated. Representative images of fibrotic 
areas in the different groups are shown in Figure 2A. Compared with the control 
group, treatment with ASA, clopidogrel, ticagrelor, and prasugrel decreased cardiac 
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fibrosis. It was more significantly reduced in the group pretreated with antiplatelet 
drugs than in the posttreatment and control groups (Fig. 2B–E). The differences in 
cardiac fibrosis between the control and drug treatment groups were statistically 
significant (p < 0.05). In a comparison of different antiplatelet drugs, the clopidogrel 
group had a larger fibrotic area after MI compared with that in the ASA, ticagrelor or 
prasugrel group (Fig. 2F, p < 0.05); these differences were statistically significant. 
 
ASA, clopidogrel, ticagrelor, and prasugrel pretreatment reduces infiltration of 
inflammatory cells in the myocardium 
Inflammatory processes are known to result in myocardial injury and impair 
cardiac function after an MI. A histopathological examination was conducted of the 
tissue sections to evaluate the extent of infiltration of inflammatory cells. The 
representative images of CD45+ staining in the different study groups are presented 
in Figure 3A. A decreased infiltration of inflammatory cells was observed in ASA, 
clopidogrel, ticagrelor, and prasugrel groups compared with that in the control group 
(Fig. 3B–E). The groups pretreated with antiplatelet drugs demonstrated lesser 
infiltration of inflammatory cells than post-treatment and control groups. Differences 
in the infiltration of inflammatory cells in the control and experimental groups were 
statistically significant (p < 0.05). The number of CD45+ positive cells in the 
clopidogrel group was higher compared with that in the ASA, ticagrelor and 
prasugrel groups, and there were significant differences among the four drugs (Fig. 
3F, p < 0.05). 
 
ASA, clopidogrel, ticagrelor, and prasugrel inhibit platelet aggregation in 
response to oxidative stress 
Platelets are activated soon after an MI, and their activation depends on the 
duration of coronary occlusion and the extent of myocardial injury. Platelet 
aggregation was measured using washed mouse platelets stimulated with thrombin. 
In the control group, thrombin-induced platelet aggregation was increased with 
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exposure to H2O2. Thrombin-induced platelet aggregation in the presence of H2O2 
was significantly inhibited by ASA, clopidogrel, ticagrelor, and prasugrel (Fig. 4). 
Ticagrelor and prasugrel were used at lower doses than ASA and clopidogrel; 
nonetheless, they demonstrated similar inhibitory effects on thrombin-induced 
platelet aggregation (Fig. 4). 
 
DISCUSSION 
The main findings of the present study were that ASA, clopidogrel, ticagrelor, 
and prasugrel pre-treatment improved cardiac function, reduced cardiac fibrosis, 
decreased infiltration of inflammatory cells into the myocardium after MI, in cases 
where reperfusion therapy was not performed, and inhibited platelet aggregation 
under oxidative stress. 
In China, morbidity and mortality from AMI are increasing year by year. In the 
past two decades, the death rate of coronary heart disease in China has doubled to 1 
million per year [12]. However, the provision of coronary reperfusion therapy varies 
greatly in patients with AMI. The China PEACE-Retrospective Acute Myocardial 
Infarction Study [13] showed that the proportion of patients who did not receive 
reperfusion was 44.8% in 2001 and 45.0% in 2011. The China AMI (CAMI) registry 
[14] showed that among patients with non-STEMI, 9.3% received an early invasive 
approach. Among patients with STEMI, only 43.0% were treated with primary PCI; 
besides, 9.9% received thrombolytic therapy. In many other developing countries this 
phenomenon may even be less optimistic. Recanalization with PCI and thrombolytic 
therapy are not always available, and other approaches have been taken to limit 
damage caused by MI. The clinical benefits of ASA, clopidogrel, ticagrelor, and 
prasugrel in STEMI patients undergoing reperfusion therapy have been previously 
confirmed in clinical trials [6, 15, 16]. Brener et al. [8] showed that pretreatment with 
ASA for 5–7 days reduced mortality at 30 days among patients with acute coronary 
syndromes; all patients accepted revascularization within 72 h. Manjyot et al. [17] 
recently reported that pretreatment with ticagrelor protected against 
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ischemia-reperfusion injury and limited the infarct size in rats. At present, primary 
prevention by aspirin is highly controversial. Sanmuganathan et al. [18] showed that 
ASA treatment for primary prevention is safe and worthwhile at coronary event risk ≥ 
1.5%/year, safe but of limited value at coronary risk 1%/year, and unsafe at coronary 
event risk 0.5%/year. Raju et al. [19] suggested that ASA prevents death, MI, and 
ischemic stroke. Moreover, it would help reduce hemorrhagic stroke as well as major 
bleeding when used in the primary prevention of cardiovascular disease. However, as 
shown in a recent research, Aspirin in Reducing Events in the Elderly (ASPREE) trial 
[20–22], the use of aspirin in healthy elderly people who did not have known 
cardiovascular disease failed to prolong disability-free survival but led to a higher 
rate of major hemorrhage than placebo, which suggests that the use of ASA is not 
reasonable for primary prevention. In conjunction with the results of the present study, 
it was believed that primary prevention with antiplatelet drugs may bring significant 
clinical benefits for people with high risk factors of MI as well as for those who are 
not able to receive reperfusion therapy in time. In particular, the use of aspirin will let 
the economically underdeveloped countries become key beneficiaries, as aspirin does 
have a cost advantage and is easy to obtain. 
In the current study, the cardiac function after an MI was significantly preserved 
on antiplatelet pre-treatment compared with that in the post-treatment and control 
groups. These results suggest a mechanism for reduction in 30-day mortality reported 
in previous studies [8]. Clopidogrel was less effective than ASA, ticagrelor, and 
prasugrel with regard to improving the LVEF and LVFS in mice in each of the treated 
groups. The dosage of each drug was based on human clinical dosage. Because 
different medications showed similar platelet inhibition, differences in the 
improvement of cardiac function with the use of the four drugs suggests that the 
protective effects might occur through mechanisms other than platelet inhibition. 
Vilahuret et al. [23] suggested that ticagrelor, but not clopidogrel, exerted 
cardioprotective effects via adenosine-dependent mechanisms.  
The adult cardiomyocyte has a limited capacity to regenerate after injury, and 
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the reparative scarring process after MI is critical for maintaining the structural 
integrity of the ventricular wall. Reparative scarring is followed by remodeling of the 
surrounding myocardium and eventually leads to impaired cardiac function [11]. It 
was reported [29] that activated platelets participate in the recruitment and activation 
of white blood cells in injured areas, release a large number of cytokines and tissue 
repair factors, and promote the occurrence of inflammatory response in injured areas, 
while the latter promotes the process of myocardial fibrosis. Antiplatelet drugs can 
effectively inhibit activation or aggregation of platelets, thus reducing the degree of 
myocardial fibrosis after MI. Some studies [24, 25] demonstrated that inhibition of 
platelet activation by clopidogrel prevented cardiac inflammation and fibrosis in 
response to angiotensin II-induced hypertension. In this study, compared with the 
control group, mice treated with ASA, clopidogrel, ticagrelor, or prasugrel 
demonstrated decreased cardiac fibrosis. This might be related to platelet inhibition 
as suggested in previous studies, and these findings are consistent with the effects of 
antiplatelet pretreatment on cardiac function after an MI.  
An intense inflammatory response is triggered after MI, which has been 
implicated in the pathogenesis of post-infarction remodeling and heart failure [26]. 
The activated platelets not only bind to different subsets of leukocytes, but also 
secrete mediators that induce transendothelial migration [27]. In the present study, 
decreased infiltration of inflammatory cells was observed after MI in the ASA, 
clopidogrel, ticagrelor, and prasugrel treatment groups compared with that in the 
control group, especially in those mice pretreated with antiplatelet drugs. 
When MI occurs, ROS are acutely produced in an ischemic microenvironment 
[28] and are major mediators of distal embolization, microvascular obstruction, and 
inflammatory response [30]. It was reported [31] that H2O2 alone does not affect 
platelet aggregation. H2O2 dose-dependently promotes low-level thrombin-induced 
human platelet aggregation. To simulate oxidative stress after MI, platelets were 
incubated with H2O2. The effects of ASA, clopidogrel, ticagrelor, and prasugrel on 
platelet aggregation under oxidative stress was investigated in this study. Results 
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herein showed that platelet aggregation, stimulated with H2O2, was inhibited 
significantly by these four drugs. These results suggest that inhibition of platelet 
activity was associated with limiting myocardial fibrosis and reducing inflammatory 
cell infiltration, thereby improving cardiac function. 
 
Limitations of the study 
There are several limitations of the present study. Firstly, the cardiac function 
was evaluated on the seventh day after MI, and therefore, there is a need for 
evaluating long-term effects of pretreatment with these drugs. Secondly, the 
European Society of Cardiology states that assessment in large animal models is an 
obligatory step before initiating human trials; thus, results of the current study should 
be verified in other animal models. Finally, the elucidation of mechanisms 




Pretreatment with ASA, clopidogrel, ticagrelor, and prasugrel can improve the 
cardiac function after MI. Pretreatment with these agents may reduce harm caused by 
MI in patients not receiving reperfusion therapy. 
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Figure 1. Acetylsalicylic acid (ASA), clopidogrel, ticagrelor, and prasugrel 
pretreatment preserved cardiac function after myocardial infarction (MI) in vivo; A. 
Representative M-mode echocardiograms for wild type, post-treatment, pre-treatment, 
and pre + post treatment mice on day 7 post MI; B–I. Echocardiographic 
quantification of left ventricular ejection fraction (LVEF) and left ventricular 
fractional shortening (LVFS). Compared with the control group, the ASA, clopidogrel, 
ticagrelor, and prasugrel pretreated mice demonstrated improved LVEF and LVFS; J, 
K. Comparisons of the four different antiplatelet drugs; clopidogrel was less effective 
in improving mice cardiac LVEF and LVFS, when compared to ASA, ticagrelor, and 
prasugrel (mean ± standard error, n = 10, *p < 0.05, #p < 0.01 vs. control, t test for 
statistical analyses). 
 
Figure 2. Pretreatment with acetylsalicylic acid (ASA), clopidogrel, ticagrelor, and 
prasugrel decreased cardiac fibrosis; A. Representative images of fibrotic area in 
 16 
different study groups stained with the Masson trichrome stain on day 7 post 
myocardial infarction (MI). Red represents viable myocardium and blue represents 
fibrosis; B–E. Quantification of Masson trichrome positive staining; F. Comparison 
of different antiplatelet drugs, clopidogrel had a larger fibrotic area after MI 
compared with ASA, ticagrelor and prasugrel (mean % of left ventricular area, n = 
10/group, *p ≤ 0.05, #p < 0.01 vs. control, t test for statistical analyses). 
 
Figure 3. Myocardial white blood cell infiltration. CD45+ staining on day 7 post 
myocardial infarction in the mouse model; A. Representative images of CD45+ 
positive staining in different groups; B–E. Quantification of CD45+ positive cells in 
the different study groups; F. Comparison of different antiplatelet drugs, CD45+ 
positive cells were more in the clopidogrel group compared with acetylsalicylic acid, 
ticagrelor and prasugrel. Immunohistochemical staining was quantitatively analyzed 
using ImageJ (magnification × 200). Data are shown as the mean white blood cell 
count per high powered field (mean ± standard error, n = 6; *p < 0.05, t test for 
statistical analyses). 
 
Figure 4. Acetylsalicylic acid (ASA), clopidogrel, ticagrelor, and prasugrel inhibited 
mouse platelet aggregation with oxidative stress; A–D. Washed mouse platelets were 
stimulated with H2O2 (200 μmol/L) for 3 min. Thrombin induced aggregation of 
mouse platelets was diminished by ASA, clopidogrel, ticagrelor, and prasugrel in a 
dose-dependent manner. At least five independent experiments were performed. 




